Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Trial of PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II)

NCT06639607 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT06639607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06639607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Trial of PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II)
Lead sponsor
Washington University School of Medicine
Phase
Phase 1/2
Overall status
Suspended
Start date
September 30, 2026
Completion date
June 30, 2051
Enrollment
68 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse midline glioma, diffuse midline high-grade glioma, ependymoma, medulloblastoma